Imposing the Enforcement Law to stop ⛔ the sale of antimicrobial agents over the counter alongwith implementation of antimicrobial stewardship can bring a dramatic shift towards decline in AMR

we should help each other to stop antibiotic abuse

Can you answer the following questions ahead of joining the Global Antibiotic Resistance live session?

A 56-year-old male presents with symptoms of fever, chills, and confusion. Blood cultures grow Klebsiella pneumoniae, which is resistant to carbapenems. The patient has a history of a recent hospitalization in India where he was treated for a urinary tract infection. Initial antimicrobial susceptibility testing indicates resistance to carbapenems (e.g., meropenem and imipenem) and other beta-lactams but susceptibility to aztreonam. The clinical microbiology laboratory performs additional testing to identify the resistance mechanism. A combination-disk test with imipenem and EDTA shows a marked reduction in MIC when EDTA is added. Immunochromatographic testing identifies the NDM carbapenemase.

Can you answer these questions on the case:

1. What diagnostic tests can be used to rapidly detect MBL-producing bacteria, and what are the key differences between phenotypic and genotypic methods?
2. How do EDTA-based tests work to confirm the presence of MBLs, and what are their limitations when applied to different bacterial species?
3. What are the advantages and limitations of PCR and immunochromatographic methods in identifying MBL-producing bacteria?
4. How can susceptibility testing results help infer the presence of an MBL enzyme, and what patterns are indicative of MBL production?
5. Why might in vivo activity of MBLs differ from in vitro results, and how can this affect therapeutic decision-making?

This program is funded by an independent grant from Pfizer Global Medical Grants. This online education program has been designed solely for healthcare professionals globally. The content is not available for healthcare professionals in the United States or Canada.

Can you answer the following questions relating to antibiotic resistance

A 70-year-old patient with a history of multiple comorbidities, including atrial fibrillation, diabetes mellitus, chronic renal disease, and a history of severe COVID-19 pneumonia requiring prolonged mechanical ventilation and tracheostomy, presents with recurrent infections. Based on the patient's medical history and recent clinical presentation, including fever, hypotension, and the identification of Klebsiella pneumoniae producing NDM, can you answer the following questions?

1. Clinical Presentation: What are the key clinical features that suggest an infection caused by an MBL-producing organism in this patient?
2. Clinical Presentation: How does the clinical presentation of this infection differ from a typical Klebsiella pneumoniae infection?
3. Risk Factors: What risk factors in this patient's history predisposed them to MBL-producing bacterial infection?
4. Diagnostic Approach: What additional diagnostic tests or investigations would you consider to confirm the presence of MBL-producing organisms and guide antimicrobial therapy?
5. Therapeutic Considerations: What are the challenges in treating infections caused by MBL-producing organisms?
6. Infection Prevention and Control: What infection prevention and control measures should be implemented to prevent the further spread of MBL-producing organisms in the hospital setting?

This program is funded by an independent grant from Pfizer Global Medical Grants. This online education program has been designed solely for healthcare professionals globally. The content is not available for healthcare professionals in the United States or Canada.